Form 4: Phathom Pharmaceuticals Director Acquires RSUs

Phathom Pharmaceuticals, Inc. reports that Director Frank Karbe acquired 24,122 Restricted Stock Units (RSUs) on May 19, 2026, under the company's Non-Employee Director Compensation Program.

Summary

• Frank Karbe, a Director at Phathom Pharmaceuticals, Inc., acquired 24,122 Restricted Stock Units (RSUs) on May 19, 2026.
• These RSUs were granted under the company's Non-Employee Director Compensation Program.
• The RSUs are set to vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided Karbe continues to serve on the Board.
• Each RSU represents a contingent right to receive one share of Phathom Pharmaceuticals' common stock.
• Following this transaction, Karbe beneficially owns 91,622 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director equity grant rather than a significant financial event or strategic shift.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The grant of RSUs aligns director compensation with long-term shareholder value creation.
• The acquisition is part of a structured compensation program for non-employee directors.

Risks

• Vesting of RSUs is contingent upon continued service on the Board, meaning potential forfeiture if service ceases before vesting.
• The value of the RSUs is tied to the performance of Phathom Pharmaceuticals' common stock, which is subject to market volatility.

Future Outlook

The future outlook for the acquired RSUs depends on the continued service of the reporting person and the company's stock performance, as vesting is tied to these factors.

Industry Context

StockSavvy.ai notes that director equity grants are a common practice in the biopharmaceutical industry to incentivize leadership and align their interests with shareholders, especially during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The grant of RSUs to directors is a standard compensation practice that can align management's interests with shareholder value, but also dilutes ownership slightly.

Next Steps

• Vesting of RSUs on the first anniversary of the grant date or the next annual stockholder meeting, contingent on continued service.
• Reporting person's continued beneficial ownership of Phathom Pharmaceuticals' common stock.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, RSUs, Equity Grant, Beneficial Ownership